Midea MASTER Series Refrigerators Midea MASTER Series Refrigerators BERLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- At Midea, we're committed to constantly innovating, elevating the performance of home appliances that enhance our everyday lives to be more efficient, effective and simply better. Therefore, we’re proud to showcase the latest in our lineup of home refrigerators across four product series here at IFA, with models featuring cutting-edge technologies including AI-powered cooling optimization and f ...

Core Insights - Firefly Neuroscience, Inc. has announced a partnership with HealingMaps and Advanced Behavioral Strategies to enhance access to its AI-driven brain health analytics platform for clinics specializing in ketamine and psychedelic-assisted therapies [1][2][5] - The collaboration follows the launch of the Healing Health Alliance, a Group Purchasing Organization aimed at supporting clinics in the psychedelic therapy space [2] - Firefly's platform utilizes non-invasive EEG assessments and AI to provide objective brain health analytics, addressing the limitations of traditional subjective assessments in neurological and mental health care [3][9] Company Overview - Firefly Neuroscience is an AI company focused on improving brain health outcomes through innovative solutions, with a proprietary database of over 180,000 EEG/ERP brain scans, making it the largest known repository of its kind [6] - The company's technology is FDA-510(k)-cleared and aims to revolutionize diagnostic and treatment monitoring for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD [6] Benefits of the Partnership - The partnership allows clinics to access Firefly's objective brain health analytics, which can enhance treatment outcomes and create new revenue opportunities [5][9] - The platform provides measurable brain health changes correlated to treatments, improving patient confidence and engagement in their care [9]

Core Insights - Health In Tech has announced strategic leadership appointments to enhance AI utilization and accelerate growth [1][5] - The company is preparing to launch a next-generation AI Engine aimed at delivering real-time insights and automating decision-making [5] Leadership Appointments - Dustin Plantholt has been appointed as Chief Artificial Intelligence & Marketing Officer, focusing on AI strategy and marketing initiatives [2][4] - Zain Hasan joins as Head of Revenue and Growth, responsible for scaling national sales operations and enhancing partnerships [2][6] Strategic Importance of AI - The CEO, Tim Johnson, emphasized that AI is central to the company's future strategy, highlighting Plantholt's expertise in AI and growth leadership [3][4] - The upcoming AI Engine is seen as a foundational milestone in transforming the company into an indispensable ecosystem partner [5] Background of New Leaders - Plantholt has extensive experience in AI architecture and was recognized as Entrepreneur's Metaverse Advisor of the Year in 2022 [4][6] - Hasan has a strong track record in the benefits and insurance sector, having successfully led organizations through acquisitions and built national distribution networks [6][7]

Core Insights - iBio, Inc. has reported transformative progress in its fiscal year 2025, focusing on advancing its pipeline in cardiometabolic diseases and obesity, with significant developments in antibody therapies [2][3] Financial Results - Revenues for the fiscal year ended June 30, 2025, were approximately $0.4 million, an increase of $0.2 million compared to fiscal year 2024 [8] - Research and Development (R&D) expenses increased to $8.3 million from $5.2 million in the previous year, primarily due to higher spending on consultants and outside services [9] - General and Administrative expenses decreased to approximately $10.7 million from $11.7 million, attributed to reduced personnel-related costs and lower insurance premiums [10] - The company reported a net loss of $18.4 million for the fiscal year, compared to a net loss of $24.9 million in the previous year [16] Pipeline Developments - iBio has developed a differentiated preclinical portfolio, including IBIO-610, which demonstrated a 26% reduction in fat mass without loss of lean mass in a study involving diet-induced obese mice [5] - The company is advancing IBIO-600, a long-acting anti-myostatin antibody, through pharmacokinetics studies showing extended half-life and dose-dependent muscle growth [5] - A bispecific antibody targeting myostatin and activin A is being developed to promote weight loss and muscle preservation [5] Corporate Developments - iBio began trading on the Nasdaq Stock Market under the ticker symbol "IBIO," enhancing visibility and trading liquidity [4] - The company raised $6.2 million through a warrant inducement transaction and completed a $50 million public offering, with potential total gross proceeds of up to $100 million [13] - The Board was expanded with industry veterans to strengthen leadership in capital markets and antibody development [13] Strategic Focus - The company is committed to leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for unmet medical needs in cardiometabolic diseases, obesity, and cancer [12]

Core Viewpoint - NextGen Digital Platforms Inc. has appointed Mark Creaser as an advisor, enhancing its position in the decentralized AI sector and Web3 infrastructure [1][2]. Group 1: Appointment of Mark Creaser - Mark Creaser is the CEO of DSV Fund and a recognized leader in the Bittensor ecosystem, bringing extensive expertise and network reach in decentralized AI [2][3]. - His appointment is expected to strengthen NextGen's validator operations, subnet investments, and TAO-related strategies [2][4]. Group 2: Background of Mark Creaser - Under Creaser's leadership, DSV Fund has executed a targeted OTC strategy, securing high-value subnet positions and partnerships with key founders in the Bittensor network [3][4]. - Creaser has a proven track record in scaling and advising companies across various sectors, holding a BA in Economics and Government from the University of Manchester [5]. Group 3: Incentive Stock Options - In connection with his appointment, the Company has granted Creaser 200,000 incentive stock options exercisable at $0.50 per share for five years, with vesting beginning four months from the grant date [6]. Group 4: About NextGen Digital Platforms Inc. - NextGen Digital Platforms Inc. is a publicly listed fintech and digital asset company focused on providing exposure to a diversified portfolio of Web3 technologies and blockchain infrastructure [7]. - The Company is committed to developing innovative financial structures that align with decentralized finance while prioritizing transparency and regulatory compliance [7].

Company Overview - Aris Mining Corporation was founded in September 2022 with a focus on becoming a leading gold mining company in Latin America, emphasizing production, cash flow generation, and transformational growth through asset expansions and exploration projects [3] - The company operates two underground gold mines in Colombia: Segovia Operations and Marmato Complex, which produced a total of 210,955 ounces of gold in 2024 [4] Recent Developments - The successful commissioning of a second mill at Segovia Operations in June 2025 has increased processing capacity by 50%, from 2,000 tonnes per day (tpd) to 3,000 tpd [7] - Milling rates have significantly increased, averaging 2,415 tpd in July and August 2025, compared to 1,971 tpd in the first half of 2025 [7] - Year-to-date gold production at Segovia as of August 31, 2025, totals 141,893 ounces, with 42,817 ounces produced in July and August [7] Production Goals - Aris Mining is on track to meet its full-year 2025 production guidance of 230,000 to 275,000 ounces of gold [2] - The company aims for an annual production rate exceeding 500,000 ounces of gold following the ramp-up of the second mill and the construction of the Bulk Mining Zone at the Marmato Complex, expected to start production in H2 2026 [4] Strategic Initiatives - Aris Mining is actively pursuing partnerships with Colombia's small-scale mining sector to promote safe, legal, and environmentally responsible operations that benefit local communities [5] - The company operates a 51% owned joint venture at Soto Norte, which has completed a Preliminary Feasibility Study (PFS) confirming it as a high-quality, long-life project with strong economics [4]

Core Insights - The venture capital firm Solaire Partners will manage a KRW 40 billion (~USD $28 million) fund backed by Korea's three leading IPTV operators to finance 3-4 major films annually [2][4] - The fund aims to revitalize the IPTV VOD market, which has been challenged by the growth of OTT platforms, and to create a sustainable ecosystem for Korea's video content industry [3][4] Fund Highlights - The 'Solaire IPTV Video Investment Fund' focuses on securing high-quality content optimized for IPTV platforms and accelerating the delivery of new releases to viewers [4] - The IPTV market has seen a significant revenue decline in paid VOD, particularly in films, dropping from the second most popular viewing method in 2018 to fourth place in 2023 [4] Investment Strategy - Solaire Partners plans to leverage over 13 years of film industry data for quantitative analysis and insights from a team with over 100 years of collective experience [5] - The firm has a portfolio that includes successful films such as 'Parasite' and '12.12: The Day' [5][10] Strategic Vision - The fund management appointment enhances K Wave Media's value chain in content production, investment, and marketing following its acquisition of AI-powered digital content company Rabbit Walk [6] - The initiative aims to create a virtuous cycle where platforms and content producers thrive together, enhancing viewer satisfaction [7] Company Overview - K Wave Media (KWM) is focused on creating, distributing, and monetizing high-quality content across multiple platforms and has been pursuing strategic growth initiatives since going public in 2025 [8][9] - Solaire Partners is recognized for its data-driven investment approach and has established itself as a trusted partner in Korea's entertainment industry [10]

Group 1 - Jyske Realkredit A/S will list a new Covered Bond (SDO) on 10 February 2025, with final terms attached to the announcement [1] - The full prospectus for the bonds includes the final terms and the previously disclosed base prospectus dated June 27, 2025 [2] - The base prospectus is available on Jyske Realkredit's official website [2]

Core Insights - The article discusses the promising initial results from the Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, highlighting significant increases in α-Gal A activity among patients [1][4][3] Company Overview - uniQure N.V. is a gene therapy company focused on developing transformative therapies for severe medical conditions, including Fabry disease [1][10] - The company has previously achieved a milestone with its gene therapy for hemophilia B, showcasing its commitment to advancing genomic medicine [10] Clinical Trial Details - The Phase I/IIa trial of AMT-191 includes multiple cohorts, with the first cohort (Cohort A) showing α-Gal A activity increases of 27- to 208-fold above normal levels [3][4] - All patients in the first cohort discontinued enzyme replacement therapy (ERT) and maintained stable plasma lyso-Gb3 levels [3][4] - A second cohort (Cohort B) has been enrolled with a lower dose, and no serious adverse events (SAEs) have been reported to date [5] Safety and Efficacy - Preliminary data indicate that AMT-191 has a manageable safety profile, with some SAEs observed that were unrelated to the treatment [4][5] - The trial aims to explore the safety, tolerability, and early efficacy of AMT-191, with updated results expected in the first half of 2026 [1][6] Disease Context - Fabry disease is a genetic disorder caused by α-Gal A enzyme deficiency, leading to harmful substrate accumulation affecting various organs [2][9] - The current standard treatment involves bi-weekly ERT, which has limitations in effectiveness [9] Regulatory Status - AMT-191 has received Orphan Drug and Fast Track designations from the U.S. FDA, indicating its potential significance in treating Fabry disease [7]

Core Points - Bunker Hill Mining Corp. has entered into an agreement for a bought deal private placement to raise C$45,000,000 by issuing 375,000,000 units at C$0.12 per unit [1][2] - Each unit consists of one common share and one warrant, with the warrant allowing the purchase of a share at C$0.17 for 60 months [2] - The offering is expected to close on September 29, 2025, subject to regulatory approvals [7] Financial Details - A cornerstone investor is expected to subscribe for approximately US$19,600,000, while another is expected to subscribe for US$5,000,000 [4] - The net proceeds will be used for advancing the construction of the Bunker Hill Mine and for general corporate purposes [5] - The underwriters will receive a cash commission of 6.0% of the gross proceeds and non-transferable compensation options equal to 6.0% of the units sold [8] Regulatory and Compliance - The offering is being made to eligible purchasers in Canada and other mutually agreed jurisdictions, subject to compliance with regulatory requirements [6] - The securities will be subject to a statutory hold period of four months and one day in Canada [10]